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Extensive respiratory chain defects in inhibitory interneurones in patients with
mitochondrial disease
Aims: Mitochondrial disorders are among the most fre-
quently inherited cause of neurological disease and arise
due to mutations in mitochondrial or nuclear DNA. Cur-
rently, we do not understand the specific involvement of
certain brain regions or selective neuronal vulnerability
in mitochondrial disease. Recent studies suggest γ-
aminobutyric acid (GABA)-ergic interneurones are par-
ticularly susceptible to respiratory chain dysfunction. In
this neuropathological study, we assess the impact of
mitochondrial DNA defects on inhibitory interneurones
in patients with mitochondrial disease. Methods:
Histochemical, immunohistochemical and immuno-
fluorescent assays were performed on post-mortem brain
tissue from 10 patients and 10 age-matched control indi-
viduals. We applied a quantitative immunofluorescent
method to interrogate complex I and IV protein expression
in mitochondria within GABAergic interneurone popula-
tions in the frontal, temporal andoccipital cortices.Wealso
evaluated the density of inhibitory interneurones in serial
sections to determine if cell losswas occurring.Results:We
observed significant, global reductions in complex I expres-
sion within GABAergic interneurones in frontal, temporal
and occipital cortices in the majority of patients. While
complex IV expression is more variable, there is reduced
expression in patients harbouring m.8344A>G point
mutations and POLG mutations. In addition to the severe
respiratory chain deficiencies observed in remaining
interneurones, quantification of GABAergic cell density
showed a dramatic reduction in cell density suggesting
interneurone loss. Conclusions:We propose that the com-
bined loss of interneurones and severe respiratory defi-
ciency in remaining interneurones contributes to impaired
neuronal network oscillations and could underlie develop-
mentof neurologicaldeficits, suchascognitive impairment
and epilepsy, in mitochondrial disease.
Keywords: cognition, epilepsy, interneurones, mitochondrial DNA, respiratory chain deficiency.
Introduction
Mitochondrial diseases are heterogeneous disorders char-
acterized by a wide-ranging spectrum of clinical symp-
toms and fluctuating disease progression. Mitochondrial
diseases are the result of primary respiratory chain dys-
function caused by either mitochondrial (mtDNA) or
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nuclear DNA mutations. Neurological deficits, along
with neuromuscular involvement, are characteristic of
mitochondrial disease, and these symptoms can have a
dramatic impact on patient quality of life. Neurological
features may be manifold, ranging from neural deafness,
ataxia, peripheral neuropathy, migraine, seizures,
stroke-like episodes and dementia and depend on the part
of the nervous system affected [1]. Though recent
neuropathological studies are expanding our understand-
ing of neural impairment and cell loss in the brains of
patients withmitochondrial disease, themechanisms con-
tributing to specific pathological processes remain to be
elucidated.
Recent electrophysiological studies suggest fast-spiking,
γ-aminobutyric acid (GABA)-ergic inhibitory inter-
neurones are particularly vulnerable to disruption of
complexes I and IV of the mitochondrial respiratory chain
[2,3]. This is not surprising as fast-spiking inhibitory
interneurones are thought to consume much more
energy than other cell types in the brain, and this
increased energy requirement originates from their ability
to generate and sustain repetitive, high-frequency action
potentials that control complex neuronal network oscilla-
tions, known as gamma oscillations. Compared with
pyramidal neurones that only display intermittent firing
patterns, interneurones have elevated firing patterns
which are required to support a greater metabolic load
through maintenance of ionic homeostasis. Anatomical
studies support the notion of a functional heterogeneity of
interneurones with respect to metabolic demands.
Interneurones contain a high density of mitochondria
and are enriched with cytochrome c oxidase (COX) and
cytochrome c; this is likely to reflect the importance of
oxidative phosphorylation in supporting their high meta-
bolic capacity [4,5].
In the current study, we aim to establish the degree to
whichGABAergic inhibitory interneurones are affected by
mitochondrial respiratory chain deficiencies and to deter-
mine the extent of interneurone loss in post-mortem brain
tissues from patients with mitochondrial disease.
Methods
Clinical assessment of patients
We investigated a total of 10 adult patients with geneti-
cally and clinically well-defined mitochondrial disease
who donated their brain for research purposes upon their
death. These patients harboured different genetic defects
including m.3243A>G mutation (n = 4), m.8344A>G
mutation (n = 2), single large-scale mtDNA deletion
(n = 1) and autosomal recessive POLG mutations (n = 3).
We retrospectively analysed the clinical course which
was typically assessed using a validated rating scale,
Newcastle Mitochondrial Disease Adult Rating Scale
(NMDAS) [6], and were therefore able to document neu-
rological deficits including ataxia, stroke-like episodes,
epilepsy and cognitive decline (Table 1). None of the
patients included in this study died from their epilepsy
(Table S1).
Post-mortem brain tissue
Brain tissues were processed for neuropathological exami-
nation as previously described [11], with one hemisphere
snap-frozen and the other fixed in formalin and paraffin-
embedded. In addition to the 10 brains from patients with
mitochondrial disease, 10 age-matched controls with no
antecedent history of seizures or strokes were included to
allow a direct comparison (Table S1). There were no sig-
nificant differences in either the age at death (t-test
P = 0.9499) or post-mortem interval (PMI; t-test
P = 0.5567). Ethical approval for this study was provided
by the Newcastle and North Tyneside Local Research
Ethics Committee.
To examine the interneuronal populations in these
patients, we focussed our investigations on the following
brain regions: frontal lobe (Brodmann area 9 –
dorsolateral prefrontal cortex), temporal lobe (Brodmann
area 21 – inferior temporal cortex) and occipital lobe
(Brodmann area 17 – primary visual cortex) in 10
patients and 10 controls. Brain regions of interest (ROIs)
were selected on the basis of recognized lobar predilection
of pathological involvement in the different genotypes
including occipital lobe which is commonly involved in
patients harbouring POLG mutations, and temporal
cortex in patients with m.3243A>G mutations while the
frontal cortices are often described as relatively spared and
hence used as a relative control ROI.
Sequential COX and succinate
dehydrogenase histochemistry
Sequential COX and succinate dehydrogenase (SDH)
histochemistry were performed on three non-serial frozen
sections as previously described [12]. This allows
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visualization of COX-deficient, SDH-positive neurones
(blue staining) and the COX-positive neurones (brown
staining). All neurones within 10 mm2 grey matter band
were counted and classified as COX-deficient (or COX
intermediate which are defined as partially COX deficient
and have a blue–grey appearance) or COX positive. From
this data, the percentage COX-deficient neurones were
determined.
Immunofluorescent identification of respiratory
chain-deficient GABAergic interneurones
As COX/SDH histochemistry only provides information
about COX-deficient SDH-positive cells, we developed an
immunofluorescent assay to specifically label GABAergic
neurones using glutamic acid decarboxylase 65–67
(GAD65-67), a commonly affected nuclear-encoded
subunit of complex I [NADH dehydrogenase (ubiquinone)
1 beta subcomplex subunit 8 (NDUFB8)], a mito-
chondrially encoded subunit of complex IV [COX subunit
1 (COX1)] and amarker of mitochondria (porin). This was
performed on one 5 μm formalin-fixed paraffin-embedded
(FFPE) section from frontal, temporal and occipital cortex
from each individual patient and control, and a similar
method has been described previously [13]. Our proce-
dure briefly involves deparaffinization and rehydration of
the sections followed by antigen retrieval by immersion in
1 mmol EDTA pH 8 in a pressure cooker for 40 min and
washing in distilled water. Sections were blocked in tris-
buffered saline with 1% tween-20 (TBST) containing 10%
goat serum for 2 h at room temperature. Mouse monoclo-
nal antibodies against NDUFB8 (Abcam UK Ab110242;
diluted 1:100), COX1 (Abcam UK Ab14705; diluted
1:200), porin (Abcam UK Ab14734; diluted 1:200) and a
rabbit polyclonal antibody directed against GAD65-67
(Sigma UK G5163; diluted 1:1000) diluted in 10% goat
serum made up TBST and incubated overnight at 4°C.
This was followed by three washes in TBST, and then IgG
subtype-specific secondary anti-mouse antibodies conju-
gated with Alexa Fluor 488, 546 and 647 (Life Technolo-
gies, UK) and a secondary anti-rabbit Alexa Fluor 405
(Life Technologies, UK) antibody diluted 1:100 in 10%
goat serum made up in TBST. These were incubated with
the sections for 2 h at 4°C. Following this, sections were
washed in three washes of TBST and then incubated in
0.3% Sudan Black for 10 min. This was followed by
washing in distilled water and mounting in Prolong Gold
(Life Technologies, UK).
Imaging and densitometric analysis
Imaging of stained sections was performed using the
epifluorescence Axio Imager M1 (Zeiss) microscope.
Inhibitory interneurones were identified by GAD65-67-
positive staining, and >40 neurones per case were imaged
independent of cellular morphology or protein abun-
dance. For densitometric analysis of the target proteins,
Image J software (U. S. National Institutes of Health,
Bethesda, Maryland, USA, version 1.46r) was used, and
images from the four channels were imported as an image
sequence. The background signal for all antibodies was
determined in a no primary control section. Cells were
outlined manually according to their GAD65-67 signal.
Within these defined areas, mean signal intensities of all
channels were determined simultaneously using the
‘analyse stack’ function in Image J and an optical density
(OD) value derived.
Statistics
The background-corrected OD values were not normally
distributed and therefore required square root transforma-
tion to normalize the data. Linear regression of trans-
formed NDUFB8 (NDUFB8T) data against transformed
porin (porinT) data and transformed COX1 (COX1T) data
against porinT data was performed to ensure the residuals
of the regression were normally distributed, and the
standard error of estimate was determined. For each
interneurone, the z score for the porin (porinz) was calcu-
lated, and the scores for NDUFB8 (NDUFB8z) and COX1
(COX1z) were derived by using the linear regression based
on the level of porin. Finally, interneurones were classified
based on standard deviation limits (for NDUFB8 or COX1:
normal if z >−2SD, low if z <−2SD, deficient if z <−3SD and
very deficient if z <−4SD). All statistical analyses were
carried out using sas 9.3 (SAS Institute Inc., Cary, NC,
USA).
Immunohistochemical staining and
two-dimensional neurone counting
FFPE frontal, temporal and occipital tissues were acquired
and stained for identification of GABAergic inhibitory
interneurones (anti-GAD65-67; Sigma 1:000) using a
polymer kit and visualization with DAB as previously
described [11]. A two-dimensional neuronal cell counting
protocol was employed as previously described with slight
4 N. Z. Lax et al.
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modification [7]. Briefly, an area of at least 20 μm2 was
outlined along a cortical ribbon encompassing cellular
layers I – VI at ×2 magnification within each Brodmann
area. As ischaemic-like lesions were frequent in these
patients, only unaffected areas of the cortex were quanti-
fied. Positive neurones as identified by dark brown chro-
mogen staining within this area were counted at ×40
magnification and the neuronal cell densities (given as
number per square millimeter) calculated for each region.
This was performed on two sections separated by at least
30 μm. To determine percentage interneurone cell loss,
the mean for each patient was divided by the mean
interneurone density from all controls; this value was
then multiplied by 100 to give percentage cell density of
control. The percentage cell loss was then calculated by
100% cell density.
Molecular biology to quantify mutation load in
homogenate tissues
The percentage heteroplasmic mutant load was deter-
mined by pyrosequencing for specific point mutations in
homogenate frozen frontal, temporal or occipital tissues as
previously described [7].
Results
Neurological manifestations in patients
Clinical symptoms including neurological impairments
are summarized where available by Table 1. In this study,
all patients investigated displayed encephalopathic find-
ings on electroencephalogram investigation. Eight of 10
patients had epilepsywhich took a variety of forms includ-
ing focal and generalized tonic–clonic or myoclonic sei-
zures. The patient harbouring a single large-scale mtDNA
deletion (patient 7) did not have epilepsy which is entirely
consistent with previous reports in the literature [14], and
the other patient (patient 10) that did not have epilepsy
harboured POLG mutations and had a primarily chronic
progressive external opthalmoplegia (CPEO) phenotype
and was elderly when he died. Stroke-like episodes were
also common and featured in six patients of which four
patients harboured the m.3243A>G mutation, one
patient harboured the m.8344A>G mutation (patient 6)
and one harboured autosomal recessive mutations in
POLG (patient 8). Patients showed signs of cognitive
decline or dementia which are prominent features in
patients with mitochondrial disease.
COX deficiency in CNS tissues
Sequential COX/SDH histochemistry reveals the presence
of COX-deficient cells throughout the CNS (Figure 1). The
long PMI for patient 2 did not appear to negatively affect
either COX or SDH enzyme activity in all CNS regions
assayed; though COX activity was certainly deficient in
some neurones, there weremultiple neurones which dem-
onstrated high activity (strong DAB reaction product),
while SDH activity was high in neurones and blood vessels
that were COX-deficient. Analysis of the frontal, temporal
and occipital tissues highlights COX-deficiency present in
neurones. Quantification of the percentage of neurones
harbouring COX-deficiency revealed the highest percent-
age of COX-deficient neurones in patients harbouring
m.8344A>G, while other patients had COX-deficient neu-
rones at lower levels (summarized in Table 2). Almost all
patients (including those harbouring POLG mutations)
demonstrated COX-deficiency within blood vessels and
white matter tracts. Although this provides information
about the distribution and extent of COX-deficiency, this
method is limited as it does not distinguish exactly which
cells are most vulnerable and assessment of COX/SDH
histochemistry is subjective.
Respiratory chain deficient
inhibitory interneurones
Wedefined respiratory chaindeficiencyas a loss or reduced
immunoreactivity of either NDUFB8 or COX1 proteins,
despite high immunoreactivity of porin for mitochondria
within a GABAergic inhibitory interneurone cell body.
Throughout all cortical regions assessed, we detected a
range of respiratory chain deficiencies within GABAergic
interneurones by quadruple immunofluorescent staining
(Figure 2). We visually confirmed that control GABAergic
neurones showed co-localization of NDUFB8, COX1 and
porin implying intact mitochondrial respiratory chain
protein expression in these cells. However, in patient
tissues, there was an obvious lack of co-localization due to
a loss of NDUFB8 and COX1 expression despite high
expression of porin in GABAergic interneurones. It was
clear that the inhibitory interneurone populations exhibit
respiratory chain deficiencies to varying levels in all CNS
regions in all patients.
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NDUFB8 expression was typically more affected than
COX1 indicating more complex I deficiency though this
patternwasvariable. Patientsharbouring them.3243A>G
mutation and single large-scale mtDNA deletion showed a
more specific loss or reduced expression of NDUFB8 while
COX1 expression appears relatively intact. Patients har-
bouring the m.8344A>G point mutation or POLG muta-
tions showed combined deficiencies of complexes I and IV
(Figure 2). Loss of NDUFB8 and COX1 expression may
occur with increased porin levels in patient interneurones
(Figure 2).
Quantification of OD for NDUFB8, COX1 and porin was
performed within each GAD65-67 positive neuronal cell
body, and to determine respiratory chain deficiency, the
OD data were transformed with linear regression for
NDUFB8 vs. porin and COX1 vs. Porin, and z scores were
derived (as shown in Figure 3). In this study, we used
negative z scores of magnitude 3 or less to indicate respira-
tory chain deficiency, and based on this, we determined
the percentage of interneurones exhibiting respiratory
chain deficiency (Table 3).
Our quantitative data show interneurones display
prominent deficiencies for complex I in almost all patients
with fewer complex IV-deficient cells throughout all three
CNS regions investigated (Figure 3 and Table 3). In agree-
ment with visual observations, interneurones sampled
from patients harbouring the m.3243A>G mutation
exhibit the greatest deficiency for NDUFB8, while COX1
involvement is minimal (Table 3). Quantification shows
evidence of combined complex I and IV deficiency in
patients harbouring m.8344A>G (patient 5) and POLG
mutations (patient 8 and 9). Intriguingly, patient 10
(POLG) demonstrates very mild respiratory chain defi-
ciency in interneurones with most being preserved,
though it is important to note this patients’ clinical course
wasmild and he had a CPEO phenotype, whereas patient 8
Figure 1. Sequential COX/SDH histochemistry reveals COX-positive (brown) cells are present in the CNS of a control individual, while
patient CNS tissues reveal a mosaic pattern of COX-positive and COX-deficient (blue) cells. Here, representative images have been captured
from control, patient with m.3243A>G (patient 3), patient with m.8344A>G (patient 6) and patient with mutations in POLG (patient 9)
grey matter and white matter regions in the occipital lobe. Control tissues demonstrate COX-positive (respiratory normal) cells throughout
all regions investigated, while patient tissues show both COX-positive and COX-deficient cells affecting neurones, blood vessels and glia. Scale
bar = 100 μm.
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(POLG) had an early-onset, Alpers’-like devastating
disease course.
GABAergic interneurone cell loss in
mitochondrial disease
We demonstrated that GABAergic cell density is reduced
throughout all cortical regions assessed in the majority of
patients relative to their control counterparts (Figure 4).
Quantification of GAD65-67-positive cells and therefore
GABAergic cell density revealed a reduction in all regions
examined suggesting widespread and, in some patients, a
high percentage (>50%) loss of GABAergic cells through-
out the CNS (Figure 4 and Table 4). This analysis did
not reveal that any particular CNS region was more vul-
nerable than another. There is also variability in the
immunoreactivity for GAD65-67 with the majority of
patients revealing a loss of positive staining in neuritic
processes which implies that inhibitory neurotrans-
mission may be affected. We evaluated whether there was
a correlation between respiratory chain deficiency involv-
ing complex I and complex IV and the percentage of
interneurone loss. Though there was a positive trend with
increasing cell loss and increased respiratory chain defi-
ciency in remaining cells, this did not reach statistical sig-
nificance (Spearman’s rank correlation coefficient).
Table 2. COX deficiency throughout the frontal, temporal and occipital cortices
Patient
% COX-deficient
neurones
COX-deficient
neuropil
COX-deficient cells
in white matter
COX-deficient
blood vessels
Frontal cortex
Patient 1 0 No No No
Patient 2 37 Yes Yes Yes
Patient 3 10 No No Yes
Patient 5 62 Yes Yes Yes
Patient 6 59 Yes * Yes
Patient 7 2 No Yes Yes
Temporal cortex
Patient 1 2 No Yes Yes
Patient 2 26 Yes Yes Yes
Patient 3 37 Yes Yes Yes
Patient 5 64 Yes Yes Yes
Patient 6 82 Yes Yes Yes
Patient 7 8 Yes Yes Yes
Occipital cortex
Patient 3 24 Yes Yes Yes
Patient 5 75 Yes Yes Yes
Patient 6 88 Yes Yes Yes
Patient 7 27 Yes Yes Yes
Patient 8 27 Yes Yes Yes
Patient 9 36 Yes Yes Yes
Patient 10 36 Yes Yes Yes
*There was no white matter present on the frontal lobe section obtained for patient 6, and therefore, this could not be assessed.
Table 3. Percentage of GABAergic interneurones exhibiting complex I and IV deficiency
Controls Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
Frontal cortex
% NDUFB8 deficiency 0.3 73 89 47 75 96 36 69 100 96 2
% COX1 deficiency 0.2 5 0 0 0 45 5 3 8 17 0
Temporal cortex
% NDUFB8 deficiency 0 69 79 18 66 40 21 33 37 0
% COX1 deficiency 0.5 4 16 0 5 15 5 2 4 0
Occipital cortex
% NDUFB8 deficiency 0 50 100 79 68 100 100 94 9
% COX1 deficiency 0 0 98 49 17 39 100 33 4
Interneurone pathology in mitochondrial disease 7
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Percentage mutant load in frontal, temporal and
occipital homogenates
Percentage m.3243A>G and m.8344A>Gmutation loads
determined in homogenate tissues are shown in Table 5.
Molecular analysis showed that the level of mutation did
not vary across the three brain regions and was greater
than 79% in all patients analysed.
Discussion
We investigated the neuropathology of 10 adult patients
with mitochondrial disease to determine whether inhibi-
tory interneurones are particularly vulnerable to mtDNA
defects and could feasibly contribute to altered neuronal
network circuitry in the brain. Using a quadruple
immunofluorescent technique, we provide clear evidence
Figure 2. Quadruple immunofluorescence allows visualization of mitochondrial respiratory chain proteins including complexes I and IV in
conjunction with mitochondrial mass within GABAergic interneurones in the inferior temporal lobe. Here, representative images have been
captured of GABAergic inhibitory interneurones (GAD65-67-positive cells which are delineated by white dashed line) from control,
m.3243A>G, m.8344A>G and POLG individuals in the inferior temporal cortex. Control GABAergic interneurones show equal expression of
complex I (NDUFB8) and complex IV (COX1) and mitochondria (porin) which colocalize in the merged image. In m.3243A>G, there is a
specific loss of NDUFB8, while COX1 and porin remain intact. Both m.8344A>G and POLG show a combined loss of NDUFB8 and COX1
while mitochondrial density is high. Scale bar = 10 μm.
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Figure 3. Extensive respiratory chain deficiency involving complex I and to a lesser degree complex IV is evident in GABAergic
interneurones throughout the CNS in patients with mitochondrial disease. Data represents z scores derived from the quantitative assessment
of NDUFB8 and COX1 optical densities relative to porin optical densities within GABAergic interneurones in patients and controls. The data
show how much the complex I and IV expression (relative to porin) deviates from normality. Here, a z score of −2 to +2 indicates normal
expression (dashed blue lines demonstrate upper and lower limits of normal expression), while a z score above 2 indicates higher expression,
and a z score lower than −2 indicates reduced expression. There is marked complex I deficiency, while complex IV deficiency is only slight in
comparison in all patient interneurones.
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Figure 4. GABAergic interneurone loss is evident in frontal, temporal and occipital cortices in patients with mitochondrial disease relative
to age-matched controls. Quantification of GAD65-67-positive cells in frontal (A), temporal (B) and occipital (C) cortices are shown as bars
with mean ± standard deviation. In all patients, there is a clear reduction in the density of GABAergic interneurones in all brain regions
assessed. In addition to reduced number of GAD65-67-positive cells, there is also variability in immunoreactivity with a propensity towards
reduced expression within the neurites of patients’ tissues relative to controls. Scale bar = 100 μm.
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of combined respiratory chain deficiencies involving com-
plexes I and IV, despite high mitochondrial mass, in
GABAergic interneurones throughout the CNS of patients
with mitochondrial disease. The overall density of
GABAergic interneurones is reduced in many of these
patients, implying reduced inhibitory neurotransmission
which could contribute to altered network dynamics in
the brains of patients. This raises the possibility that a loss
of inhibitory interneurones might lower the amount of
inhibitory activity in the brain and could contribute to
phenotypes, including epilepsy and cognitive decline.
Recent electrophysiological evidence implicates a vul-
nerability of fast-spiking inhibitory interneurones to per-
turbed energy metabolism [2,3,15]. The evidence for this
vulnerability stems from the high energy requirement of
these cells to produce complex, high-frequency action
potentials allowing them to exert local control over
large populations of pyramidal neurones. Inhibitory
GABAergic interneuronesmodulate excitation and inhibi-
tion in the cerebral cortex [16] and thereby contribute to
local control of microcircuitry, shaping information
outputs from the excitatory pyramidal neurones which
transmit information throughout thebrain todifferent cor-
tical areas. The balance of excitation and inhibition is
crucial, and without this, the threshold for developing
pathological conditions, such as epilepsy or impaired cog-
nition, might be lowered. Indeed, dysfunction or a loss of
GABAergic interneurones has been recognized as a poten-
tial contributor to lowering seizure threshold [17–19].This
work shows that there is indeedwidespreadmitochondrial
respiratory chain deficiency in inhibitory interneurones in
patients with mitochondrial disease, and this might con-
tribute to altered network dynamics in the brains of these
patients.
In this study, we used a quadruple immunofluorescent
approach to accurately quantify respiratory chain defi-
ciency by measuring complex I and IV subunit expression
in conjunction with mitochondrial mass in GABAergic
interneurone populations in patients with mitochondrial
disease. This method provides an unbiased, reproducible,
precise and detailed analysis of mitochondrial respiratory
chain deficiency which can be modified to include other
subunits of the mitochondrial respiratory chain or used
to evaluated different cell types. Our data reveal exten-
sive respiratory chain deficiencies affecting inhibitory
interneurones, with a marked reduction in complex I and
IV expression in patients with mitochondrial disease rela-
tive to age-matched controls. Complex I deficiency exceeds
complex IV deficiency which is a consistently reported
neuropathological finding in patients with mitochondrial
disease [20,21] and is a common pathological finding
in other neurological disorders, including Parkinson’s
disease [22] and temporal lobe epilepsy [23].
We next investigated interneurone population density
to determine the impact of respiratory chain deficiency on
interneurone cell loss. We observed a widespread and
extensive decrease in interneurone density throughout all
brain regions analysed in the majority of patients. An
exception to this is patient 7 (single mtDNA deletion)
where the density of interneurone was similar to control
densities in frontal cortex, and higher than in other
patients in temporal and occipital cortices. All quantifica-
tion was performed in areas of the cortex that were spared
and did not show features consistent with laminar dehis-
cence or necrotic lesions. What is interesting is the trend
towards interneurone loss, affecting all regions including
the frontal cortex. Pathology in these patients is often
described in posterior regions [12,24], though in our clini-
cal experience, frontal lobe involvement is not uncom-
Table 4. Percentage of GABAergic neurone cell loss in patients
(patient neurone density/average control neurone density × 100)
Patient
Frontal
cortex (%)
Temporal
cortex (%)
Occipital
cortex (%)
Patient 1 58 67 Not available
Patient 2 81 62 Not available*
Patient 3 74 49 67
Patient 4 72 50 87
Patient 5 81 68 70
Patient 6 59 73 67
Patient 7 0 39 44
Patient 8 96 92 81
Patient 9 68 82 88
Patient 10 52 63 60
*Data for patient 2 are not available as the occipital cortex was com-
pletely devastated by a necrotic ischaemic-like lesion.
Table 5. Percentage mutant load in homogenate CNS tissues
Patient
Frontal
cortex
Temporal
cortex Occipital cortex
Patient 1 79 83 Not available
Patient 2 93 93 94
Patient 3 90 94 92
Patient 5 92 92 93
Patient 6 87 88 88
Interneurone pathology in mitochondrial disease 11
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
mon. In fact, ischaemic-like lesions in frontal lobes were
documented in four patients in this study, including
patient 1 (m.3243A>G), patient 2 (m.3243A>G), patient
9 (POLG) and patient 10 (POLG) which suggests greater
brain involvement than perhaps originally perceived
[25,26]. Indeed, high heteroplasmy levels of mutated
mtDNAwere detected in homogenate DNA extracted from
all three brain regions. Interneurone pathology in these
frontal regions may also influence other pathological pro-
cesses recognized in mitochondrial disease, including
neuropsychiatric manifestations and cognitive decline
[27]. Indeed, cognitive decline has been reported in
patients with mitochondrial disease previously [28,29],
and a loss of calbindin-positive interneurones is impli-
cated in the development of cognitive impairments in
patients harbouring the m.3243A>G mutation [30].
Interneurone cell loss was extensive in the majority of
patients but was less severe in patient 7 (single large-scale
deletion) and patient 10 (POLG) where GABAergic
interneurones were onlymoderately decreased. Pathology
in patients harbouring large-scale mtDNA deletions pre-
dominantly results from spongiform degeneration of the
white matter tracts and is associated with cerebellar
ataxia and cognitive impairment [14,31]. Patient 10
(POLG) presented with mitochondrial disease later in life
and principally exhibited a CPEO phenotype without overt
neurological involvement, and this may account for why
there was very little respiratory chain deficiency in his
interneurones and a moderate loss of interneurones.
Our data show extensive involvement of the inter-
neurones in mitochondrial disease, and we believe that
interneurone pathology due to respiratory chain defi-
ciency and cell loss might contribute to altered neuronal
network dynamics in the brain which is responsible for
neurological deficits seen in these patients. Electroen-
cephalogram data from these patients certainly provides
evidence in support of impaired neuronal networks in
mitochondrial disease, and we believe that interneurone
dysfunction and cell loss could be one factor contributing
to abnormal neuronal activity. In those patients where
interneurone loss is high it is interesting to note that the
clinical course was generally dominated by severe neuro-
logical impairments including stroke-like episodes, sei-
zures and cognitive decline. Although other factors, such
as mitochondrial dysfunction in other cell types, may con-
tribute and certainly may have an additive effect on devel-
opment and severity of neurological disease. Certainly,
COX/SDH histochemistry reveals that COX-deficiency
affects multiple cell types including neurones, vascular
and glial cells (Figure 1). The contribution of mito-
chondrial impairments in these cellsmaymodify neuronal
network oscillations and may be an important factor for
the development of multiple neurological features, includ-
ing stroke-like episodes and epilepsy [32]. Therefore, it
would be important to assess the degree of mitochondrial
impairment in these cells.
Though neuropathological investigation of post-
mortem brain tissue from patients with mitochondrial
disease is limited as pathology often represents end-stage
disease and patients with severe end-stage disease are
much more likely to have had severe neurological condi-
tions, we believe this study has provided clear evidence of
mitochondrial dysfunction in GABAergic interneurones.
We believe interneurone dysfunction is an important
finding and might be one of the pathological processes
contributing to altered neuronal oscillations to promote
development of impaired neurological function in these
patients. This work offers an important platform from
which further work can be completed to understand how
mitochondrial respiratory chain deficiencies affect distinct
neuronal populations.
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